Johnson & Johnson Raises 2025 Outlook After Strong Cancer, Medtech Sales

Johnson & Johnson reported strong second-quarter 2025 results, with adjusted earnings per share of $2.77 and revenues of $23.74 billion, both surpassing analyst expectations. Growth was primarily driven by its oncology drugs, notably Darzalex which generated $3.54 billion in sales, and its medtech division, which saw a 7.3% increase led by cardiovascular and wound closure products. Despite setbacks from declining Stelara sales and COVID-19 impacts, the company raised its full-year sales outlook to $93.2 billion-$93.6 billion and increased its adjusted earnings guidance to $10.80-$10.90 per share. Johnson & Johnson also reduced its expected tariff costs due to a delay in new US-China trade tariffs, which CEO Joe Wolk said reflects an understanding of the complexities in biopharmaceutical manufacturing. Investor confidence was bolstered by the company’s strong performance and outlook, with analysts rating the stock as an 'Outperform' and projecting significant upside potential. The results highlight sustained demand for innovative cancer treatments and medtech products, underscoring the sector's resilience amid geopolitical and market challenges.